Mackeen A Dhanya, Packard Roger E, Ota Erika, Speer Linda
Division of Maternal Fetal Medicine, Women's Health Service Line, Geisinger Health System, 100 N Academy Ave, Danville, PA, USA, 17822.
Cochrane Database Syst Rev. 2015 Feb 2;2015(2):CD001067. doi: 10.1002/14651858.CD001067.pub3.
Postpartum endometritis occurs when vaginal organisms invade the endometrial cavity during the labor process and cause infection. This is more common following cesarean birth. The condition warrants antibiotic treatment.
Systematically, to review treatment failure and other complications of different antibiotic regimens for postpartum endometritis.
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 November 2014) and reference lists of retrieved studies.
We included randomized trials of different antibiotic regimens after cesarean birth or vaginal birth; no quasi-randomized trials were included.
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy.
The review includes a total of 42 trials, and 40 of these trials contributed data on 4240 participants.Regarding the primary outcomes, seven studies compared clindamycin plus an aminoglycoside versus penicillins and showed fewer treatment failures (risk ratio (RR) 0.65, 95% confidence interval (CI) 0.46 to 0.90). There were more treatment failures in those treated with an aminoglycoside plus penicillin when compared to those treated with gentamycin/clindamycin (RR 2.57, 95% CI 1.48 to 4.46). There were more treatment failures (RR 1.66, 95% CI 1.01 to 2.74) and wound infections (RR 1.88, 95% CI 1.08 to 3.28) in those treated with second or third generation cephalosporins (excluding cephamycins) versus those treated with clindamycin plus gentamycin. In four studies comparing once-daily with thrice-daily dosing of gentamicin, there were fewer failures with once-daily dosing. There were more treatment failures (RR 1.94, 95% CI 1.38 to 2.72) and wound infections (RR 1.88, 95% CI 1.17 to 3.02) in those treated with a regimen with poor activity against penicillin-resistant anaerobic bacteria as compared to those treated with a regimen with good activity against penicillin-resistant anaerobic bacteria. There were no differences between groups with respect to severe complications and no trials reported any maternal deaths.Regarding the secondary outcomes, three studies that compared continued oral antibiotic therapy after intravenous therapy with no oral therapy, found no differences in recurrent endometritis or other outcomes. Four trials that compared clindamycin plus aminoglycoside versus cephalosporins identified fewer wound infections in those treated with clindamycin plus an aminoglycoside (RR 0.53, 95% CI 0.30 to 0.93). There were no differences between groups for the outcomes of allergic reactions. The overall risk of bias was unclear in the most of the studies. The quality of the evidence using GRADE comparing clindamycin and an aminoglycoside with another regimen (compared with cephalosporins or penicillins) was low to very low for therapeutic failure, severe complications, wound infection and allergic reaction.
AUTHORS' CONCLUSIONS: The combination of clindamycin and gentamicin is appropriate for the treatment of endometritis. Regimens with good activity against penicillin-resistant anaerobic bacteria are better than those with poor activity against penicillin-resistant anaerobic bacteria. There is no evidence that any one regimen is associated with fewer side-effects. Following clinical improvement of uncomplicated endometritis which has been treated with intravenous therapy, the use of additional oral therapy has not been proven to be beneficial.
分娩过程中阴道微生物侵入子宫内膜腔并引发感染时,会发生产后子宫内膜炎。这种情况在剖宫产术后更为常见。该病症需要进行抗生素治疗。
系统评价产后子宫内膜炎不同抗生素治疗方案的治疗失败及其他并发症情况。
我们检索了Cochrane妊娠与分娩组试验注册库(2014年11月30日)以及检索到的研究的参考文献列表。
我们纳入了剖宫产或阴道分娩后不同抗生素治疗方案的随机试验;未纳入半随机试验。
两位综述作者独立评估试验是否纳入及偏倚风险,提取数据并检查其准确性。
该综述共纳入42项试验,其中40项试验提供了4240名参与者的数据。关于主要结局,7项研究比较了克林霉素加氨基糖苷类与青霉素类,结果显示治疗失败较少(风险比(RR)0.65,95%置信区间(CI)0.46至0.90)。与庆大霉素/克林霉素治疗组相比,氨基糖苷类加青霉素治疗组的治疗失败更多(RR 2.57,95%CI 1.48至4.46)。与克林霉素加庆大霉素治疗组相比,第二代或第三代头孢菌素(不包括头霉素)治疗组的治疗失败更多(RR 1.66,95%CI 1.01至2.74),伤口感染也更多(RR 1.88,95%CI 1.08至3.28)。在4项比较庆大霉素每日一次与每日三次给药的研究中,每日一次给药的失败较少。与对青霉素耐药厌氧菌活性良好的治疗方案相比,对青霉素耐药厌氧菌活性较差的治疗方案的治疗失败更多(RR 1.94,95%CI 1.38至2.72),伤口感染也更多(RR 1.88,95%CI 1.17至3.02)。两组在严重并发症方面无差异,且无试验报告任何孕产妇死亡。关于次要结局,3项比较静脉治疗后继续口服抗生素治疗与不进行口服治疗的研究发现,复发性子宫内膜炎或其他结局无差异。4项比较克林霉素加氨基糖苷类与头孢菌素的试验发现,克林霉素加氨基糖苷类治疗组的伤口感染较少(RR 0.53,95%CI 0.30至0.93)。两组在过敏反应结局方面无差异。大多数研究中总体偏倚风险不明确。使用GRADE比较克林霉素和氨基糖苷类与另一种治疗方案(与头孢菌素或青霉素类相比)的证据质量,在治疗失败、严重并发症、伤口感染和过敏反应方面为低至极低。
克林霉素和庆大霉素联合适用于治疗子宫内膜炎。对青霉素耐药厌氧菌活性良好的治疗方案优于对青霉素耐药厌氧菌活性较差的治疗方案。没有证据表明任何一种治疗方案的副作用更少。对于经静脉治疗后病情改善的非复杂性子宫内膜炎,额外使用口服治疗尚未被证明有益。